AzTrials
AzTrials

Sleep Disorders Not Due to A Substance or Known Physiological ConditionFrench-RCSQNCT06945874

Validity and Reliability of the French Translation of the Richards-Campbell Questionnaire

An observational study of Sleep Disorders Not Due to A Substance or Known Physiological Condition, run by University Hospital, Rouen at 2 sites in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The validation of a sleep questionnaire (translated into French from a source questionnaire in English) will provide a reliable and easily administered tool for assessing sleep quality in intensive care, enabling better identification of patients at risk of sleep disorders and other associated complications, in… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Validation of sleep quality by the Richards-Campbell Sleep Questionnaire (RCSQ) in french version
How many people
190 participants
Where
2 sitesFrance
Study dates
12 May 2025to 1 May 2026
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The RCSQ-F questionnaire will be distributed at the same time as the ISI and Epworth questionnaires to ICU patients who meet the inclusion and non-inclusion criteria and who have given their informed consent to participate in the study. The questionnaires will be distributed on two occasions: at the first visit and on the day of discharge from intensive care.

Who may be able to join

  • Patient aged ≥ 18 years
  • Hospitalised in intensive care for at least 24 hours
  • Able to understand and answer questionnaires
  • Unsedated (discontinued for 24 hours) presenting a Richmond Sedation Agitation Scale score between ≥-2 and ≤ +1
  • Fluent in French
  • Having given oral consent for participation in the study
  • Person affiliated to a social security scheme.

Who cannot join

  • Patient refusal
  • Person deprived of liberty by an administrative or judicial decision or protected adult subject (under guardianship or curatorship)
  • Patient unable, for whatever reason, to read, understand or answer the questionnaires (visual problems, psychiatric or cognitive problems, etc.)
  • Patient already included in the study or another study evaluating sleep

Trial locations and contacts

2 sites in 1 country.

France2 sites
  • University Hospital of Poitiers

    Poitiers, 86021

  • University Rouen Hospital

    Rouen, 76031

Other trials in France

About this study

Official title: Validity and Reliability of the French Translation of the Richards-Campbell Questionnaire for Assessing Sleep in the Intensive Care Unit

The validation of a sleep questionnaire (translated into French from a source questionnaire in English) will provide a reliable and easily administered tool for assessing sleep quality in intensive care, enabling better identification of patients at risk of sleep disorders and other associated complications, in particular ventilatory weaning difficulties.

Read the detailed description

Sleep disturbance in intensive care is influenced by a number of factors, such as environmental nuisances (noise, light, repeated interruptions), treatments (sedation, analgesia, mechanical ventilation) and the severity of the acute pathology that led to admission. Consequences include alterations to the immune system, neuropsychiatric disorders and impaired functional recovery.

Current management of these disorders remains limited:

  • No pharmacological treatment has clearly demonstrated its efficacy on sleep quality in intensive care.
  • Interventions aimed at modulating environmental nuisances (reducing noise, reducing light exposure, respecting day/night cycles) have shown limited effects.
  • According to the available data, individual devices (eye masks, earplugs) have not significantly improved sleep architecture.

In this context, the Richards-Campbell questionnaire (RCSQ) represents an interesting alternative for subjectively assessing sleep in intensive care patients. This questionnaire, specifically designed for these patients, provides a simple and rapid assessment of sleep disturbances. The validation of a French version of the RCSQ meets a need to standardise assessment practices in France and to gain a better understanding of the factors influencing sleep quality in intensive care.

Being tested
Validation of sleep quality by the Richards-Campbell Sleep Questionnaire (RCSQ) in french version
Keywords
sleep disorders in intensive care patients

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Validation of sleep quality by the Richards-Campbell Sleep Questionnaire (RCSQ) in french versionDiagnostic test

    The RCSQ questionnaire translated into French (RCSQ-F) will be distributed to intensive care patients who meet the inclusion and non-inclusion criteria and who have given their informed consent to participate in the study.

    The questionnaire will be distributed on two occasions: at the first visit and on the day of discharge from intensive care for survivors, or at the latest on the 14th day of hospitalisation.

    Patients' use of the questionnaire will enable internal validation (primary objective) by exploratory factor analysis.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Validation of the French translation of the Richards-Campbell questionnaire

    Assessing the internal validity of the French translation of the Richards-Campbell questionnaire for analysing sleep quality in intensive care patients

    Measured: Visit Inclusion (V1, Day 1) and Visit V2 (Day 14)

Secondary outcomes (5)
  1. Inter-rater agreement between patients and nurses

    Evaluation of inter-rater agreement between scores given by patients and nurses. The inter-judge agreement between patient and nurse (first secondary objective) will be evaluated by an intra-class correlation coefficient (single measure, absolute agreement, two-way random) on observations with neither missing data on the patient assessment nor the nurse assessment at the V1 visit.

    Measured: Visit Inclusion (V1, Day 1)

  2. Convergent validity of the results of the French RCSQ with other questionnaires

    To assess the convergent validity of the results of the French RCSQ with the Epworth scale. This convergent validity (2nd secondary objective) will be assessed by the Pearson correlation coefficient of the overall score of the RCSQ-F with the Epworth on observations with no missing data on these scales at the V1 visit.

    Measured: Visit Inclusion (V1, Day 1)

  3. Convergent validity of the results of the French RCSQ with other questionnaires

    To assess the convergent validity of the results of the French RCSQ with the ISI scale. This convergent validity (2nd secondary objective) will be assessed by the Pearson correlation coefficient of the overall score of the RCSQ-F with the ISI on observations with no missing data on these scales at the V1 visit.

    Measured: Visit Inclusion (V1, Day 1)

  4. Divergent validity of results

    Assess the divergent validity of the results by analysing the correlation between the French RCSQ and the HAD scale. This divergent validity will be assessed at V1 by calculating the Pearson correlation coefficient between the total RCSQ-F and the HAD scale: a low correlation coefficient (but not necessarily zero) is desirable: R < 0.30 ideally.

    Measured: Visit Inclusion (V1, Day 1)

  5. French RCSQ's sensitivity to change

    To assess the sensitivity to change of the French RCSQ by analysis of subjects with neither missing data at V1 nor missing data at V2 (discharge from intensive care) concerning the RCSQ-F. Sensitivity to change will be assessed by a 95% Student's confidence interval on paired series estimating the difference in standardised means (i.e. divided by the standard deviation at V1) of the total RCSQ-F. The sensitivity to change of each of the RCSQ-F items will be analysed in the same way. The correlation matrix of changes in the items between V1 and V2 will also be calculated, thus verifying the consistency of the evolutionary trends.

    Measured: Visit V2 (Day 14)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Apr 2025
  2. Study start12 May 2025
  3. Primary completion8 Apr 2026
  4. Study completion1 May 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
190 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06945874
Sponsor's protocol ID
2025/0017/OB
Other IDs
IDRCB : 2025-A00224-45
Acronym
French-RCSQ
Status last verified
Mar 2026
First submitted
9 Apr 2025
Last updated
17 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: The data provided will be the property of the sponsor and will be used solely for its own research activities.

Questions about this trial

What is this clinical trial studying?

An observational study of Sleep Disorders Not Due to A Substance or Known Physiological Condition, run by University Hospital, Rouen at 2 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Validation of the French translation of the Richards-Campbell questionnaire (time frame: Visit Inclusion (V1, Day 1) and Visit V2 (Day 14)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jun 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in